|
|||||
|
|
Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer |
|
| Authors: | FS Mennini A Marcellusi G Fabiano F Platini P Bossi |
| Abstract: | |
| Keywords: | budget cetuximab economic benefits every‐other week head and neck cancer |